Efficacy and safety of first-line therapies in EGFR-mutated advanced non-small-cell lung cancer: a network meta-analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35187947/
Aim: To evaluate the comparative efficacy and safety of identified first-line therapies for patients with EGFR mutation-positive ( EGFR m+) advanced non-small-cell lung cancer (NSCLC), with a focus on ramucirumab...
Conclusion: The analysis showed ramucirumab erlotinib efficacy to be comparable to best-in-class treatment options for previously untreated patients with EGFRm advanced NSCLC.
Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer
Source : https://www.tandfonline.com/doi/abs/10.1080/14737140.2022.2094772?journalCode=iery20
ABSTRACT Immune checkpoint inhibitors (ICI) are now utilized as a standard of care treatment for multiple cancers, including in both the metastatic setting as well as in earlier stages of...
Relevance: Immune checkpoint inhibitors (ICI) are now utilized as a standard of care treatment for multiple cancers, including in both the metastatic setting as well as in earlier stages of disease. The identification of unique immune-related adverse events (irAE) that occur during ICI treatment has led to intense research to identify...
Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics - BMC Cancer
Source : https://bmccancer.biomedcentral.com/articles/10.1186/s12885-022-09830-8
Background The survival of patients with lung cancer has substantially increased in the last decade by about 15%. This increase is, basically, due to targeted therapies available for advanced stages...
Conclusions: Despite the lack of a national project and standard protocol in Spain that regulates the determination of biomarkers, the situation is similar to other European countries. Given the growing number of different determinations and their high positivity, national strategies are urgently needed to implement next-generation sequencing...
Is the Efficacy of Adding Ramucirumab to Docetaxel Related to a History of Immune Checkpoint Inhibitors in the Real-World Clinical Practice? - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35740634/
Reports on the efficacy of second-line treatment with cytotoxic agents after treatment with immune checkpoint inhibitors are limited. Here, we retrospectively evaluated patients in the real-world clinical practice treated with...
Conclusion: “Our real-world data show that the addition of ramucirumab to docetaxel was superior to docetaxel monotherapy for improving time-to-treatment failure and overall survival, irrespective of previous treatment with immune checkpoint inhibitors.”
-
Albert Dekker3yrMay be I am missing something but I thought it was proven long ago
Effect of smoking habits on the efficacy of EGFR-TKI plus anti-angiogenic agent in advanced EGFR-mutant NSCLC - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35728482/
doi: 10.1016/j.lungcan.2022.06.006. Online ahead of print. 1 Department of Medical Oncology, Changzheng Hospital, Naval Medical University, Shanghai 200003, China. 2 Department of Medical Oncology, Changzheng Hospital, Naval Medical University, Shanghai...
Conclusion: Comprehensive analysis suggested that EGFR-TKI plus anti-angiogenic agents led to favorable PFS among smoking EGFR-mutant patients, comparable to nonsmokers, which might provide a useful guide for clinicians.